Cytotoxicity and mitochondrial apoptosis induced by etoposide in melanoma cells

Cancer Investigation

Volumn 27, Issue 7, 2009, Pages 704-717

  Rudolf, Kamil ^a   Červinka, Miroslav ^b   Rudolf, Emil ^b  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Apoptosis; ATM; Caspase 2; Etoposide; Melanoma

Indexed keywords

2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; ADENOSINE TRIPHOSPHATE; ATM PROTEIN; CASPASE 2; CASPASE INHIBITOR; CYCLOSPORIN A; CYTOCHROME C; ETOPOSIDE; HEAT SHOCK PROTEIN 27; PIFITHRIN ALPHA; PROTEIN BAX; PROTEIN KINASE INHIBITOR; PROTEIN P53; SUPEROXIDE; SURVIVIN; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; BOWES CELL; CONTROLLED STUDY; DNA DAMAGE; DNA FRAGMENTATION; DRUG CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME RELEASE; HUMAN; HUMAN CELL; MELANOMA CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; OXIDATIVE STRESS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STATISTICAL ANALYSIS; WESTERN BLOTTING;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BENZOTHIAZOLES; CASPASE 2; CASPASE 3; CASPASE 9; CELL CYCLE PROTEINS; CYCLOSPORINE; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; DNA DAMAGE; DNA-BINDING PROTEINS; ETOPOSIDE; HUMANS; MELANOMA; MITOCHONDRIA; NEOPLASM PROTEINS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; SUPEROXIDES; TOLUENE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 68849085068     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900802653480     Document Type: Article

References (37)

1. Gray-Schopfer, V.; Wellbrock, C.; Marais, R. Melanoma biology and new targeted therapy. Nature 2007, 445(7130), 851-857. (Pubitemid 46309849)
2. Cohen, C.; Zavala-Pompa, A.; Sequeira, J.H.; Shoji, M.; Sexton, D.G.; Cotsonis, G.; Cerimele, F.; Govindarajan, B.; Macaron, N.; Arbiser, J.L. Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin Cancer Res 2002, 8(12), 3728-3733.
3. Garraway, L.A.; Widlund, H.R.; Rubin, M.A.; Getz, G.; Berger, A.J.; Ramaswamy, S.; Beroukhim, R.; Milner, D.A.; Granter, S.R.; Du, J.; Lee, C.; Wagner, S.N.; Li, C.; Golub, T.R.; Rimm, D.L.; Meyerson, M.L.; Fisher, D.E.; Sellers, W.R. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005, 436(7047), 117-122.
4. Amiri, K.I.; Richmond, A. Role of nuclear factor-kappa B in melanoma. Cancer Metastasis Rev 2005, 24(2), 301-313.
5. Soegas, M.S.; Lowe, S.W. Apoptosis and melanoma chemoresistance. Oncogene 2003, 22(20), 3138-3151.
6. Grossman, D.; Altieri, D.C. Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev 2001, 20(1-2), 3-11. (Pubitemid 34074673)
7. Ivanov, V.N.; Bhoumik, A.; Ronai, Z. Death receptors and melanoma resistance to apoptosis. Oncogene 2003, 22(20), 3152-3161. (Pubitemid 36713767)
8. Selzer, E.; Schlagbauer-Wadl, H.; Okamoto, I.; Pehamberger, H.; Potter, R.; Jansen, B. Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines. Melanoma Res 1998, 8(3), 197-203. (Pubitemid 28313756)
9. Bowen, A.R.; Hanks, A.N.; Allen, S.M.; Alexander, A.; Diedrich, M.J.; Grossman, D. Apoptosis regulators and responses in human melanocytic and keratinocytic cells. J Invest Dermatol 2003, 120(1), 48-55. (Pubitemid 36120970)
10. Soengas, M.S.; Capodieci, P.; Polsky, D.; Mora, J.; Esteller, M.; Opitz-Araya, X.; McCombie, R.; Herman, J.G.; Gerald, W.L.; Lazebnik, Y.A.; Cordon-Cardo, C.; Lowe, S.W. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001, 409(6817), 207-211.
11. Tang, L.; Tron, V.A.; Reed, J.C.; Mah, K.J.; Krajewska, M.; Li, G.; Zhou, X.; Ho, V.C.; Trotter, M.J. Expression of apoptosis regulators in cutaneous malignant melanoma. Clin Cancer Res 1998, 4(8), 1865-1871. (Pubitemid 28369169)
12. Fischer, B.; Arcaro, A. Current status of clinical trials for small cell lung cancer. Rev Recent Clin Trials. 2008, 3(1), 40-61. (Pubitemid 351267025)
13. Feldman, D.R.; Bosl, G.J.; Sheinfeld, J.; Motzer, R.J. Medical treatment of advanced testicular cancer. JAMA 2008, 299(6), 672-684. (Pubitemid 351252727)
14. Baldwin, E.L.; Osheroff, N. Etoposide, topoisomerase II and cancer. Curr Med Chem Anticancer Agents 2005, 5(4), 363-372.
15. Rudolf, E.; Cervinka, M. Topoisomerases and tubulin inhibitors: a promising combination for cancer treatment. Curr Med Chem Anticancer Agents 2003, 3(6), 421-429. (Pubitemid 37236412)
16. Karpinich, N.O.; Tafani, M.; Rothman, R.J.; Russo, M.A.; Farber, J.L. The Course of etoposide-induced apoptosis from damage to DNA and p53 activation to mitochondrial release of cytochrome c. J Biol Chem 2002, 277(19), 16547-16552.
17. Lage, H.; Helmbach, H.; Dietel, M.; Schadendorf, D. Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance. Br J Cancer 2000, 82(2), 488-491. (Pubitemid 30045402)
18. Helmbach, H.; Kern, M.A.; Rossmann, E.; Renz, K.; Kissel, C.; Gschwendt, B.; Schadendorf, D. Drug resistance towards etoposide and cisplatin in human melanoma cells is associated with drug-dependent apoptosis deficiency. J Invest Dermat 2002, 118(6), 923-932. (Pubitemid 34639169)
19. Montecucco, A.; Biamonti, G. Cellular response to etoposide treatment. Cancer Lett 2007, 252(1), 9-18.
20. Lombardi, T.; Castellucci, M. Bowes human melanoma cell line. An immunocytochemical study. Virchows Archiv 1990, 58(3), 181-183.
21. Rudolf, E.; Cervinka, M. Membrane blebbing in cancer cells treated with various apoptotic inducers. Acta mMedica (Hradec Kralove) 2005, 48(1), 29-34.
22. Nagatani, T.; Okazawa, H.; Kambara, T.; Satoh, K.; Nishiyama, T.; Tokura, H.; Yamada, R.; Nakajima, H. Effect of natural interferon-beta on the growth of melanoma cell lines. Melanoma Res 1998, 8(4), 295-299. (Pubitemid 28442559)
23. Tarhini, A.A.; Agarwala, S.S. Cutaneous melanoma: available therapy for metastatic disease. Dermatol Ther 2006, 19(1), 19-25.
24. Pamment, J.; Ramsay, E.; Kelleher, M.; Dornan, D.; Ball, K.L. Regulation of the IRF-1 tumour modifier during the response to genotoxic stress involves an ATM-dependent signalling pathway. Oncogene 2002, 21(51), 7776-7785.
25. Straume, O.; Akslen, L.A. Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma. Int J Cancer 1997, 4(5), 535-539. (Pubitemid 27486512)
26. Ko, L.J.; Prives, C. p53: puzzle and paradigm. Genes Dev 1996, 10(9), 1054-1072.
27. Johnstone, R.W.; Ruefli, A.A.; Lowe, S.W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002, 108(2), 153-164.
28. Kim, R.; Emi, M.; Tanabe, K. Caspase-dependent and independent cell death pathways after DNA damage (review). Oncol Rep 2005, 14(3), 595-599.
29. Fu, X.; Wan, S.; Lyu, Y.L.; Liu, L.F.; Qi, H. Etoposide induces ATM-dependent mitochondrial biogenesis through AMPK activation. PLoS ONE 2008, 3(4), 1-10. (Pubitemid 352015927)
30. Tanizawa, A.; Kubota, M.; Hashimoto, H.; Shimizu, T.; Takimoto, T.; Kitoh, T.; Akiyama, Y.; Mikawa, H. VP-16-induced nucleotide pool changes and poly(ADP-ribose) synthesis: the role of VP-16 in interphase death. Exp Cell Res 1989, 185(1), 237-246. (Pubitemid 19284511)
31. Ly, J.D.; Grubb, D.R.; Lawen, A. The mitochondrial membrane potential (deltapsi(m)) in apoptosis: an update. Apoptosis 2003, 8(2), 115-128. (Pubitemid 36553052)
32. Finucane, D.M.; Waterhouse, N.J.; Amarante-Mendes, G.P.; Cotter, T.G.; Green, D.R. Collapse of the inner mitochondrial transmembrane potential is not required for apoptosis of HL60 cells. Exp Cell Res 1999, 251(1), 166-174.
33. Hishita, T.; Tada-Oikawa, S.; Tohyama, K.; Miura, Y.; Nishihara, T.; Tohyama, Y.; Yoshida, Y.; Uchiyama, T.; Kawanishi, S. Caspase-3 activation by lysosomal enzymes in cytochrome c-independent apoptosis inmyelodysplastic syndrome-derived cell line P39. Cancer Res 2001, 61(7), 2878-2884. (Pubitemid 32691929)
34. Robertson, J.D.; Enoksson, M.; Suomela, M.; Zhivotovsky, B.; Orrenius, S. Caspase-2 acts upstream of mitochondria to promote cytochrome c release during etoposide-induced apoptosis. J Biol Chem 2002, 277(33), 29803-29809.
35. Enoksson, M.; Robertson, J.D.; Gogvadze, V.; Bu, P.; Kropotov, A.; Zhivotovsky, B.; Orrenius, S. Caspase-2 permeabilizes the outer mitochondrial membrane and disrupts the binding of cytochrome c to anionic phospholipids. J Biol Chem 2004, 279(48), 49575-49578. (Pubitemid 39577759)
36. Read, S.H.; Baliga, B.C.; Ekert, P.G.; Vaux, D.L.; Kumar, S.A. novel Apaf-1-independent putative caspase-2 activation complex. J Cell Biol 2002, 159(5), 739-745.
37. Garrido, C.; Bruey, J.M.; Fromentin, A.; Hammann, A.; Arrigo, A.P.; Solary, E. HSP27 inhibits cytochrome c-dependent activation of procaspase-9. Faseb J 1999, 13(14), 2061-2070. (Pubitemid 29517636)